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Cholesterol is a major constituent of myelin membranes, which insulate axons and allow saltatory conduction.
Therefore, Schwann cells, the myelinating glia of the peripheral nervous system, need to produce large amounts of
cholesterol. Here, we define a crucial role of the transcription factorMaf inmyelination and cholesterol biosynthesis
and show thatMaf acts downstream fromNeuregulin1 (Nrg1). Maf expression is induced when Schwann cells begin
myelination. Genetic ablation ofMaf resulted in hypomyelination that resembled mice with defective Nrg1 sig-
naling. Importantly, loss ofMaf orNrg1 signaling resulted in a down-regulation of the cholesterol synthesis program,
and Maf directly binds to enhancers of cholesterol synthesis genes. Furthermore, we identified the molecular
mechanisms by which Nrg1 signaling regulates Maf levels. Transcription ofMaf depends on calmodulin-dependent
kinases downstream fromNrg1, whereas Nrg1–MAPK signaling stabilizesMaf protein. Our results delineate a novel
signaling cascade regulating cholesterol synthesis in myelinating Schwann cells.
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Axons of neuronsmust be insulated for efficient transmis-
sion of electrical impulses. Fast saltatory conduction of
electrical impulses relies on the presence of myelin,
which is produced by Schwann cells and oligodendrocytes
in the peripheral and central nervous system, respectively.
Impaired myelination in humans can lead to devastating
pathologies, underscoring the importance of myelin in
nervous system function. Myelin membranes have a
very high lipid content, among which the most abundant
is cholesterol. Schwann cells rely heavily on de novo cho-
lesterol synthesis rather than its uptake from the circula-
tion (Jurevics andMorell 1994). Accordingly,micewith an
impaired ability to produce cholesterol fail to myelinate
or produce thin myelin sheaths; e.g., mice with ablation
of SCAP or genes encoding cholesterol biosynthesis en-
zymes (Saher et al. 2005; Verheijen et al. 2009). Cholester-
ol synthesis is tightly regulated in most cell types, but
how Schwann cells or oligodendrocytes meet the high de-
mands for cholesterol synthesis required for myelination
is an open question.
Schwann cells derive from migrating neural crest cells
(Jessen andMirsky 2005). Schwanncell precursorsmigrate
along the axons of peripheral neurons and are demarcated
by expression of the transcription factor Sox10 and the ty-
rosine kinase receptor ErbB3 (Meyer et al. 1997; Britsch
et al. 2001). They become immature Schwann cells around
embryonic days 15–16 (E15–E16) in mice, when they sort
out axons based on their diameter to establish a 1:1 rela-
tionship with large-diameter axons. Myelination begins
around birth and depends on the transcription factors
Oct-6, Pou3f2 (Brn2), and Egr2 (Jessen and Mirsky 2005;
Svaren and Meijer 2008; Stolt and Wegner 2016). Axonal
signals provided by Neuregulin1 (Nrg1) as well as crucial
cues from the extracellular matrix mediated by integrin
andG-protein-coupled receptors control entry into the ter-
minal Schwann cell differentiation program (Chernousov
et al. 2008; Newbern and Birchmeier 2010; Herbert and
Monk 2017).
Nrg1 signals govern many aspects of Schwann cell de-
velopment (Newbern and Birchmeier 2010). During early
stages, Nrg1 signals ensure Schwann cell proliferation and
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migration along the axonal tract (Meyer and Birchmeier
1995; Lyons et al. 2005). Subsequently, Nrg1 is essential
for their entry into the myelination program (Taveggia
et al. 2005; Kao et al. 2009) and, finally, is needed during
myelination to ensure that the appropriate myelin thick-
ness is achieved (Garratt et al. 2000; Michailov et al.
2004). A particular isoform, Nrg1 type III, drives Schwann
cell development during these different stages (Meyer
et al. 1997; Michailov et al. 2004). Nrg1 type III is neuro-
nally produced and axonally presented and depends on
Bace1-dependent cleavage for its full function (Leimeroth
et al. 2002; Willem et al. 2006). Nrg1 signaling occurs
via ErbB2 and ErbB3 receptor heterodimers present in
Schwann cells. Upon Nrg1 binding, the tyrosine kinase
of the ErbB2/3 heterodimer is activated and phosphory-
lates receptors and other downstream molecules. This
creates docking sites for downstream signaling compo-
nents, which activate signaling pathways such as
MAPK, AKT, and JAK/STAT and participate in Ca2+-de-
pendent signaling (Newbern and Birchmeier 2010).
It is poorly understood how the same signaling system
can regulate the many different steps of Schwann cell de-
velopment and result in stage-specific and biologically dif-
ferent outcomes. The key to understanding this would be
to identify the downstream targets of the Nrg1–ErbB2/3
pathway that mediate each step of Schwann cell develop-
ment. Nrg1-dependent activation of NFAT and YY1 in-
duces Egr2 expression and has been implicated in the
initiation of the myelination program and in differentia-
tion of promyelinating cells (Kao et al. 2009; He et al.
2010). Once myelination begins, Nrg1 signaling activity
determinesmyelin thickness in a dose-dependentmanner
(Michailov et al. 2004). For instance, when ErbB2 is ablat-
ed using an Egr2 promoter-driven Cre after myelination
has begun, thin myelin is formed (Garratt et al. 2000).
The MAPK pathway downstream from ErbB2 promotes
the translation efficacy of myelin proteins and thereby
supports myelination (Sheean et al. 2014). The AKT path-
way and its downstream component, mTOR, also pro-
mote the production of myelin proteins and cholesterol
(Sherman et al. 2012; Norrmen et al. 2014; Domenech-
Estevez et al. 2016). However, how Nrg1 coordinates my-
elin protein production with cholesterol synthesis is ill
defined.
Maf is a member of the MAF family of bZIP transcrip-
tion factors, which either activate or repress target genes
(Blank and Andrews 1997). Maf has been implicated in
diverse developmental processes and controls differentia-
tion of the lens, hematopoietic cells, and touch-sensitive
sensory neurons (Ho et al. 1996; Kim et al. 1999; Wende
et al. 2012). However, the role of Maf in Schwann cells
has not been studied. While investigating the expression
pattern of Maf in the developing peripheral nervous sys-
tem, we noticed a robust induction of Maf in myelinating
Schwann cells. Loss ofMaf in myelinating Schwann cells
through cell type-specific genetic ablation resulted in the
formation of thinmyelin. Transcriptome analysis showed
thatMaf is required for the maximal expression of choles-
terol synthesis genes, a rate-limiting step in myelination.
This overlaps with the changes in gene expression ob-
served when ErbB2 is ablated in myelinating Schwann
cells. Interestingly, we observed that Nrg1–ErbB signals
positively regulate Maf through both transcriptional and
post-transcriptional mechanisms.
Results
Maf is expressed in myelinating Schwann cells
We first investigated the expression pattern of Maf in de-
veloping peripheral nerves. Maf is absent in sciatic nerve
tissue at E16 but is detectable at E18 and thereafter (Fig.
1A). Maf-positive cells were in close contact with axons
marked by Nf-200, suggesting that Maf is expressed in
Schwann cells. RT-qPCR analysis of sciatic nerve tissue
from different developmental stages showed that Maf
mRNA is robustly induced after E16 and reaches a plateau
at postnatal day 10 (P10) (Fig. 1B). Thus, Maf expression
mirrors that of myelin basic protein (MBP), a component
of myelin. These findings suggest that Maf expression is
initiated when Schwann cells begin to myelinate. Next,
we performed coimmunostaining with Egr2, a transcrip-
tion factor that is expressed inmyelinating Schwann cells.
In adult sciatic nerve tissue, Maf was detected in most
Egr2-positive cells (94% ± 0.68% of all Egr2+ cells were
Maf+) (Fig. 1C, arrows). Consistent with previous reports
(Nakamura et al. 2009), Maf was also present in F4/80-
positive macrophages present in the nerves (95% ±
0.76% of all F4/80+ cells were Maf+) (Fig. 1C, arrowheads).
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Figure 1. Maf is expressed in myelinating Schwann cells.
(A) Immunohistological analysis of murine sciatic nerves of the
indicated ages using anti-Maf and anti-Nf-200 antibodies. (B)
Time course ofMaf andMbpmRNA expression during myelina-
tion. Levels of Maf and Mbp mRNAs were measured by RT-
qPCR, and the levels at P15 were taken as 1. n = 3. Error bars in-
dicate SEM. (C ) Immunohistological analysis of the adult sciatic
nerve demonstrates that Maf is expressed in Egr2+ myelinating
Schwann cells (arrows) and F4/80 positive macrophages (arrow-
heads). (D) Teased nerve fibers ofMafLacZ/+ mice show that β-ga-
lactosidase is absent in nonmyelinating L1+ Schwann cells. Bars,
20 µm.
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Conversely, <1% of all Maf+ cells did not express either
Egr2 or F4/80. In teased adult fiber preparation from
MafLacZ/+ mice (LacZ is driven by theMaf locus), we con-
firmed that β-galactosidase, the protein product of the
LacZ gene, was not produced in L1-positive nonmyelinat-
ing Schwann cells (Fig. 1D). Whole-mount X-gal staining
of spinal cords revealed that β-galactosidase-expressing
cells do not accompany sensory projections once they en-
ter the central nervous system, indicating that Maf is not
present in oligodendrocytes (Supplemental Fig. S1). Taken
together, we conclude that Maf expression is specifically
initiated during myelination but is not present in non-
myelinating Schwann cells or oligodendrocytes. These re-
sults implicate Maf in Schwann cell myelination.
Loss of Maf impairs myelin growth and reduces axon
conduction velocity
To investigate the function of Maf in myelinating Sch-
wann cells, we ablated Maf specifically using the Egr2-
Cre allele (Mafflox/flox; Egr2-Cre; referred to here as
ΔMaf). Egr2, Maf, and F4/80 coimmunostaining at P8 con-
firmed an efficient ablation of Maf in Schwann cells but
not macrophages (Supplemental Fig. S2). When we exam-
ined the sciatic nerve at P8 by electron microscopy, mye-
lin sheaths of control and ΔMaf mice appeared similar
(Fig. 2A–C). However, while the thickness of the myelin
sheaths grew robustly in control mice, those of ΔMaf
mice grew poorly and were very thin at P30 (Fig. 2D–F).
In addition, at P90,myelin was thin in the sciatic and fem-
oralis nerves of ΔMaf mice (Fig. 2G–I; Supplemental Fig.
S3A–C). Quantification showed that the myelin sheaths
of small-diameter axons were less affected than those of
large-diameter axons (Fig. 2F,I). When Dhh-Cre was used
to recombine theMaf locus at the Schwann cell precursor
stage, an identical phenotypewas observed (Supplemental
Fig. S3D–F). Therefore, Maf is dispensable for the early
steps of Schwann cell development and the entry into
myelination but is specifically required during myelin
growth. Furthermore, internodal distances were reduced
in ΔMaf mice (Fig. 2J). Nonmyelinated axons were unaf-
fected, and the number per remark bundle was unchanged
(Supplemental Fig. S3G). In addition, ΔMaf mice often
displayed local areas of excessively thick myelin called
tomaculae (Fig. 2K; Supplemental Fig. S3H). These abnor-





Figure 2. Ablation of Maf inmyelinating Schwann
cells causes hypomyelination. (A–C ) Electron mi-
croscopy analysis of sciatic nerves from wild-type
or ΔMaf mice and quantification of myelin thick-
ness at P8. n = 3. (D–F ) Same as A–C at P30. n = 3.
(G–I ) Same as A–C at P90. n = 3. (J) Quantification
of internodal distances at P90. n = 3. (K ) Quantifica-
tion of the frequency of tomaculae. n = 3. (L) ΔMaf
mice have reduced axon conduction velocity. Con-
duction velocity was measured on the saphenous
nerve of control and ΔMaf mice. n = 103 fibers
from three control mice; n = 129 fibers from five
ΔMaf mice. Bars, 1 µm. Error bars indicate SEM.
For statistical analysis, unpaired two-tailed Stu-
dent’s t-test with 95% confidence interval was per-
formed. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001; (n.s.)
nonsignificant.
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disorders in both mice and humans (Adlkofer et al. 1995;
Sander et al. 2000). One mechanism known to induce
tomaculae formation is aberrant AKT activation (Goeb-
bels et al. 2012; Domenech-Estevez et al. 2016), but
AKT activity was unchanged in the peripheral nerves of
ΔMaf mutants (Supplemental Fig. S3I).
Next, we performed single-fiber conduction velocity
measurements on the saphenous nerve, a sensory branch
of the sciatic nerve. Consistent with the hypomyelination
phenotype, ΔMaf mice displayed more fibers with the
slowest conduction velocities (0–5m/sec) and fewer fibers
with the fastest conduction velocities (15–20 m/sec) (Fig.
2L). Median conduction velocities were significantly dif-
ferent; i.e., 10.6 and 6.6 m/sec in control and ΔMafmice,
respectively (Mann-Whitney U-test P < 0.0002). We con-
clude thatMaf is essential for normalmyelination and op-
timal saltatory conduction of peripheral nerves.
Loss of Maf or Nrg1 signaling results in reduced
cholesterol synthesis in Schwann cells
To understand the mechanisms underlying impaired my-
elin growth in ΔMafmice, we assessed the transcriptome
ofMaf-deficient Schwann cells bymicroarray analysis. To
exclude secondary effects, we used P8 nerves; i.e., a stage
at which myelin grows but no histological change is yet
apparent inΔMafmutants. Given that the loss ofNrg1 sig-
naling in myelinating Schwann cells results in a similar
phenotype (Garratt et al. 2000), we also obtained microar-
ray data from conditional ErbB2mutant mice at the same
stage (ErbB2flox/flox; Egr2-Cre, referred to here as ΔErbB2).
ErbB2 is an obligatory coreceptor for Nrg1 in Schwann
cells and is therefore indispensable for Nrg1 signaling. In-
terestingly, many deregulated genes in ΔMaf mice were
also deregulated in ΔErbB2, thus showing a tight positive
correlation between ΔMaf and ΔErbB2mice (Fig. 3A). Fig-
ure 3B shows a cluster analysis of differentially regulated
genes that shows a large proportion of overlapping genes
in the two mutants (clusters 1 and 4). In addition, genes
in clusters 2 and 5 were also changed in both mutants
but affected to very different extents. Importantly, many
genes in cluster 1 (strongly down-regulated genes in both
mutants) participate in cholesterol synthesis, including
the rate-limiting enzymes Hmgcr and Fdft1 (Fig. 3C).
Gene ontology (GO) analysis demonstrated a strong en-
richment of cholesterol and lipid biosynthesis terms (Sup-
plemental Fig. S4A). Deregulated expression of selected
genes encoding cholesterol synthesis enzymes was veri-
fied by RT-qPCR and Western blotting at P8 (Fig. 3D,E).
Unlike cholesterol synthesis genes, transcripts of key
Schwann cell transcription factor genes such as Egr2 and
Sox10 as well as genes encoding myelin proteins were un-
changed (Supplemental Fig. S4B). The reduced expression
of the majority of cholesterol biosynthesis genes persisted
to P30, althoughAcss2mRNAwas no longer decreased at
this late stage (Supplemental Fig. S4C).
We reported previously thatNrg1 signaling inmyelinat-
ing Schwann cells boosts global protein translation, there-
by promoting the production of myelin proteins (Sheean





Figure 3. Loss of Maf or Nrg1 signaling impairs cholesterol syn-
thesis in myelinating Schwann cells. (A) Correlation of transcript
levels between ΔMaf andΔErbB2mutantmice. Only genes dereg-
ulated in ΔMafmice were analyzed. (B) Cluster analysis of differ-
entially regulated genes. (C ) Heatmap of cholesterol biosynthesis
genes in cluster 1. (D) Validation of microarray results by
RT-qPCR at P8. n > 6. (E) Validation of transcript analysis at the
protein level at P8; the lysates analyzed are pools of nerves from
three to four mice. (F ) Box plot of the fold changes in new protein
abundance in ΔMafmutant mice as determined by in vivo pulse
SILAC (stable isotope labeling by amino acids in cell culture) ex-
periments. Identified proteins were classified into five categories:
cholesterol biosynthesis proteins (Cholest.), lipid metabolism
(Lipid Meta.), myelin, ribosomal proteins, and others. (n) The
number of identified proteins in each group. Note that global
protein production was unaffected, but cholesterol synthesis en-
zymes were produced at reduced levels in ΔMaf mutant mice.
(∗∗∗) P < 0.001 from a two-sided Wilcoxon rank-sum test (α =
0.05) (G) Cholesterol levels in ΔMaf or ΔErbB2 sciatic nerves at
P15 were determined by gas chromatography-mass spectrometry
(GC-MS).n = 4. (H) Maf binds to enhancers of genes encoding cho-
lesterol biosynthesis enzymes. Macrophage-depleted P14 rat sci-
atic nerve tissues were analyzed by ChIP-qPCR (chromatin
immunoprecipitation [ChIP] combined with quantitative PCR
[qPCR]) using anti-Maf serum (n = 4); the promoter of Gapdh
was used as negative control. All error bars indicate SEM. For
all statistical analysis except in F, unpaired two-tailed Student’s
t-test with 95% confidence interval was performed. (∗) P < 0.05;
(∗∗) P < 0.01; (∗∗∗) P < 0.001; (n.s.) nonsignificant.
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vivo pulse SILAC (stable isotope labeling by amino acids
in cell culture) in the sciatic nerves of control and ΔMaf
mice. This showed that global translation, including
that of myelin proteins, was unaffected in ΔMaf mice
(Fig. 3F). In contrast, production of all six proteins belong-
ing to cholesterol biosynthesis pathway detected by mass
spectrometry was markedly reduced in ΔMaf mice (Fig.
3F). New protein production correlated well with the
change in mRNA levels, indicating that decreased
mRNA levels caused the change in protein production
(Supplemental Fig. S4D).
Next, we measured the amount of cholesterol in P15
sciatic nerve tissues by gas chromatography-mass spec-
trometry (GC-MS). Significantly reduced cholesterol lev-
els were observed in the nerves of both ΔMaf and
ΔErbB2mice (Fig. 3G). Cholesterol is an essential andma-
jor constituent of the myelin sheath, suggesting that the
down-regulation of cholesterol biosynthesis is an impor-
tant aspect of the hypomyelination phenotype in ΔMaf
and ΔErbB2mice.
Maf binds to enhancer elements of cholesterol synthesis
genes in vivo
We aimed to understand howMaf regulates the transcrip-
tion of cholesterol synthesis genes. SREBP1/2 are the
master regulators of genes involved in lipid and cholester-
ol biosynthesis (Brown and Goldstein 1997). However,
our transcriptome data did not reveal any changes in
SREBP1/2 mRNA levels, and sciatic nerve tissue from
mutantmice had slightly higher amounts of the processed
transcriptionally active SREBP1/2, which might be due to
a compensatory mechanism (Supplemental Fig. S4E).
We then examined whether Maf directly binds to cis-
regulatory elements of cholesterol synthesis genes. Previ-
ously published H3K27ac mapping data from rat sciatic
nerve tissue were used to identify active enhancers that
were used as candidates (Lopez-Anido et al. 2015). Since
Maf is also expressed in macrophages, we depletedmacro-
phages from digested sciatic nerve tissues using magnetic
beads conjugated with an antibody against F4/80.
RT-qPCR against F4/80 confirmed that >90% of macro-
phages were depleted by this procedure. We then per-
formed chromatin immunoprecipitation (ChIP) using
anti-Maf serum followed by qPCR. This showed an en-
richment of Maf at a subset of enhancers, including
enhancers associated with the genes encoding the rate-
limiting enzymes Hmgcr and Fdft1 (Fig. 3H). In contrast,
we did not observe enrichment of Maf at myelin genes
(Supplemental Fig. S4F). These results suggest that Maf
directly participates in the transcriptional regulation of
cholesterol synthesis genes in Schwann cells.
Maf regulates expression of cholesterol biosynthesis
genes in cultured Schwann cells
Wewanted to directly test the role of Maf in inducing the
expression of cholesterol biosynthesis genes in cultured
Schwann cells. First, we overexpressed Maf in S16 cells,
an immortalized rat Schwann cell line, by retroviral trans-
duction. Cells were analyzed by RT-qPCR 3 d after infec-
tion. In addition, we also treated cells with methyl-β-
cyclodextrin (MβCD), which depletes cellular cholesterol
and thereby boosts de novo cholesterol synthesis, 24 h pri-
or to harvest. We found that Maf overexpression alone in
the absence of MβCD results in a weak but statistically
significant up-regulation of cholesterol biosynthesis
genes. When combined with MβCD, the effect of Maf
overexpression wasmore pronounced (Fig. 4A). Therefore,
Maf overexpression can enhance cholesterol biosynthesis,
especially when cells are under high demand to synthe-
size large amounts of cholesterol.
As a complimentary loss-of-function approach, we
used primary mouse Schwann cells and induced their
BA
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C Figure 4. Maf regulates expression of cholesterol
biosynthesis genes in cultured Schwann cells. (A)
S16 cells were transduced with control or Maf-ex-
pressing retroviruses, selected with puromycin to
eliminate uninfected cells, and exposed or not ex-
posed to 5mMMβCD.n = 4.mRNAsof the indicat-
ed cholesterol biosynthesis enzymeswere analyzed
by RT-qPCR. The numbers in parentheses refer to
average fold changes. (B) Scheme of the analysis of
differentiated/undifferentiated primary mouse
Schwann cells. (C ) Maf mRNA quantified by RT-
qPCR (n = 4) in differentiated and undifferentiated
Schwann cells in the presence or absence of Maf
or control siRNAs. (D) mRNA levels of the indicat-
ed genes were analyzed by RT-qPCR. n = 4. Error
bars indicate SEM. For statistical analysis, paired
two-tailed Student’s t-test with 95% confidence in-
terval was performed. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗)
P < 0.001; (n.s.) nonsignificant.
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differentiation using cAMP and Nrg1 (Arthur-Farraj et al.
2011). We transfected primary mouse Schwann cells
with control or two different Maf siRNAs and allowed
them to differentiate in the presence of db-cAMP (cell-per-
meable analog of cAMP) and Nrg1 (Fig. 4B). Cells main-
tained in the absence of db-cAMP and Nrg1 were used
as undifferentiated controls. Maf mRNA was robustly
induced by db-cAMP and Nrg1, and the siRNAs down-
regulated Maf transcripts by >90% (Fig. 4C). We then
compared the mRNA levels of Mbp, Egr2, and genes en-
coding cholesterol biosynthesis enzymes. In accordance
with the results from mutant mouse tissue, loss of Maf
suppressed the induction of genes encoding cholesterol
biosynthesis enzymes but did not affect Mbp or Egr2 ex-
pression (Fig. 4D).
Maf transcript and protein levels are decreased
in ΔErbB2 mice
Next, we analyzed upstream events controlling Maf. Giv-
en the phenotypic and transcriptomic similarities be-
tween ΔMaf and ΔErbB2 nerves, we hypothesized that
Maf is a downstream effector of Nrg1–ErbB2/3 signaling.
Intriguingly, we noticed in our microarray data that Maf
mRNAwas significantly decreased in ΔErbB2 nerves. We
validated this finding by RT-qPCR, which demonstrated
a 50%–60% reduction of Maf mRNA in ΔErbB2 nerves
compared with controls (Fig. 5A). However, at the protein
level, Maf was more strongly reduced in ΔErbB2 nerves,
and levels were almost comparable with those observed
in the nerves of ΔMaf mutants (Fig. 5B,C). The residual
Maf protein observed in ΔMaf nerves is likely produced
by macrophages in the nerve that are not recombined by
Egr2-Cre (Supplemental Fig. S2). In conclusion, our data
indicate that Nrg1–ErbB2/3 signaling regulates Maf by
two distinct mechanisms: a transcriptional one and a
post-transcriptional one. It should be noted that heterozy-
goteMafmutantmice,whichhave a 50%reduction ofMaf
mRNA, showedaverymild change inmyelination thatdid
not reach statistical significance (Supplemental Fig. S5).
Thus, the ErbB2-dependent transcriptional regulation
combined with its post-transcriptional regulation of Maf
is functionally critical.
Maf transcription is regulated by Nrg1/Ca2+/
calmodulin
We aimed to understand the transcriptional mechanism
by which Nrg1 regulates Maf. We observed that stimula-
tion of serum-starved S16 cells with recombinantNrg1 in-
ducedMafmRNA in a time-dependent manner (Fig. 6A).
Although this does not reflect a differentiation context,
we reasoned that it could serve as an experimental plat-
form to investigate the molecular mechanism, which,
once identified, can then be verified in vivo. We focused
on pathways known to be activated downstream from
Nrg1–ErbB2/3 signaling that were implicated in Schwann
cell biology (MAPK, AKT, and the Ca2+ pathway) (New-
bern and Birchmeier 2010) and tested inhibitors of these.
We additionally tested the JAK/STAT pathway because
it was also reported to be activated by Nrg1 (Liu and
Kern 2002). As expected, a specific inhibitor of the ErbB2
kinase, TAK165, abolished theNrg1-dependent induction
ofMafmRNA.However,MAPK, AKT, and JAK inhibitors
failed to blockNrg1-stimulatedMaf transcription (Fig. 6B).
In contrast, two different inhibitors of the Ca2+ signaling
pathway—an inhibitor of PLCγ and an IP3 receptor
(IP3R) antagonist—abrogated the Nrg1-dependent Maf
transcription (Fig. 6B). Conversely, raising intracellular
Ca2+ by using ionomycin induced Maf mRNA (Supple-
mental Fig. S6A).
To test this mechanism in an independent cell line,
RT4-D6P2T (referred to here as RT4) rat Schwannoma
cells were used; these cells carry an activating mutation
in the transmembrane domain of ErbB2 (V664E) (Barg-
mann et al. 1986). Overnight incubation with ErbB2 or
Ca2+ pathway inhibitors decreasedMafmRNA, and iono-
mycin antagonized the effect of ErbB2 inhibition on Maf
mRNA in RT4 cells (Supplemental Fig. S6B,C). Thus,
Ca2+ signaling regulates the levels of Maf transcripts in
two different cell lines.
Next, we tested inhibitors of major calcium effectors.
Inhibitors of the PP2B–NFAT pathway or of PKC had no
effect on Maf mRNA. However, an inhibitor of the cal-
modulin-dependent protein kinase CaM-KK completely
blocked the Nrg1-dependent induction ofMaf in S16 cells
(Fig. 6B).We also confirmed in primary Schwann cells that
inhibition of Ca2+ signaling and CaM-KK activity blocks
the induction of Maf mRNA by recombinant Nrg1 (Sup-
plemental Fig. S6D). Although CaM-KK inhibition did
not affect Maf transcript levels in RT4 cells, inhibition
of CaMKII, another calmodulin-dependent kinase that
shares most of its targets with CaM-KK (Berridge et al.
2003), reduced Maf mRNA (Supplemental Fig. S6B). This
difference might be due to cell line-specific expression
levels or activities of the two proteins. Together, our re-
sults indicate that Ca2+-mediated activation of calmodu-
lin-dependent protein kinase (CaM-KK or CaMKII)
inducesMaf transcription in Schwann cell lines.
CBA
Figure 5. Maf transcript and protein levels are decreased in
ΔErbB2 mutant mice. (A) Maf mRNA is decreased in ΔErbB2
mice. n = 4. (B,C ) Maf protein is decreased in ΔErbB2 mice. (B)
A representative Western blot image. (C ) Quantification of Maf
protein levels on Western blots. n = 10 for control; n = 10 for
ΔErbB2; n = 8 for ΔMaf. Note that the extent of the reduction of
the Maf protein is greater than that of its mRNA. Error bars indi-
cate SEM. For statistical analysis, unpaired (A) and paired (C) two-
tailed Student’s t-tests with 95% confidence interval were per-
formed. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001.
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CaM kinases exclude HDAC5 (histone deacetylase 5)
from the nucleus to derepress Maf
CaM kinases can regulate gene expression by activating
members of the CREB family of transcription factors (Ber-
ridge et al. 2003). However, overexpression of CREB or
ATF-1, two CREB familymembers known to be expressed
in Schwann cells (Arthur-Farraj et al. 2011), did not induce
MafmRNA in either S16 or RT4 cells (Supplemental Fig.
S6E). Class II HDACs, which include HDAC4 and
HDAC5, shuttle between the nucleus and cytoplasm.
CaMKII, CaMKI, or CaMKIV (CaMKI and CaMKIV are
activated by CaM-KK) phosphorylate HDAC4/5, leading
to interaction with 14-3-3 proteins, cytoplasmic reten-
tion, and derepression of target genes (Yang and Gregoire
2005). We hypothesized that HDAC4/5 represses Maf
and that CaM kinase antagonizes this repression. To
test this, we expressed Flag-tagged HDAC4/5SA mutants
in which all serine residues phosphorylated by CaM
kinases were substituted with alanine. Interestingly,
overexpression of HDAC5SA, but not HDAC4SA, down-
regulatedMafmRNA in S16 cells and abrogated Nrg1-de-
pendent stimulation of Maf transcription (Fig. 6C).
Conversely, silencing of HDAC5 by siRNA increased
the level ofMafmRNA (Fig. 6D).
We next tested HDAC5-mediated repression of Maf in
differentiating mouse primary Schwann cells. HDAC5SA
expression blocked the induction of Maf mRNA by db-
cAMP and Nrg1 (Fig. 6E). HDAC5SA expression also
impaired the induction of cholesterol biosynthesis
genes but did not affect Mbp or Egr2 (Supplemental Fig.
S6F). Next, we tested whether HDAC5 binds at the Maf
A B C
E F G
H I J K
D
Figure 6. Nrg1-dependent calcium–calmodulin kinase and HDAC5 (histone deacetylase 5) regulate Maf transcription. (A) Nrg1 induces
Maf mRNA in S16 cells. S16 cells were serum-starved and treated with Nrg1 for the indicated times, and mRNA was analyzed by
RT-qPCR. n = 3. (B) RT-qPCR analysis of Maf mRNA in S16 cells stimulated by Nrg1 and treated with the indicated inhibitors. Note
that inhibitors of ErbB2, the Ca2+ pathway, and CaM kinase abrogate Nrg1-dependent Maf transcription. n = 4. (C ) Nuclear-localized
HDAC5 repressesMaf. S16 cells were transduced with HDAC4SA or HDAC5SA retroviruses and stimulated with Nrg1. n = 4. (D) Deple-
tion ofHDAC5 inducesMaf. S16 cellswere transfectedwith two independent siRNAs against HDAC4orHDAC5.MafmRNA levelswere
measured 3 d after transfection. n = 4. (E) HDAC5SA represses Maf induction in differentiated primary mouse Schwann cells. n = 3.
(F ) HDAC5 binds to the promoter region ofMaf. S16 cells were transfected with control or siRNA against HDAC5. Cells were analyzed
byChIP-qPCRusing an anti-HDAC5 antibody. n = 3. (G) HDAC5 is regulated byNrg1. Serum-starved S16 cellswere stimulatedwithNrg1
for the indicated time points. Cells were fractionated into cytosol and nuclear lysates, and fractions were analyzed by Western blotting.
(H) Histone acetylation is increased at theMaf promoter in HDAC5 silenced S16 cells. n = 3. (I ) CamKVI and HDAC5 phosphorylation is
reduced in sciatic nerve tissues of ΔErbB2mice. n = 3. Shown is a representativeWestern blot among three pairs. (J) HDAC5 binding at the
Maf promoter is increased in sciatic nerve tissues of ΔErbB2mice. n = 3. Note that only about half of the nuclei in the nerve derive from
myelinating Schwann cells. (K ) Histone acetylation is reduced at theMaf promoter in sciatic nerve tissues of ΔErbB2mice. n = 3. All error
bars indicate SEM. For statistical analysis, paired two-tailed Student’s t-tests with 95% confidence interval were performed except for in J,
which is unpaired. (∗) P < 0.05; (∗∗) P < 0.01.
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promoter by performingChIP-qPCR (ChIP combinedwith
quantitative PCR [qPCR]) with an anti-HDAC5 antibody
(Fig. 6F). HDAC5 was enriched at the Maf promoter, and
silencing of HDAC5 abolished this enrichment, confirm-
ing the specificity of the ChIP-qPCR experiment. Further-
more, silencing of HDAC5 led to increased histone H3
acetylation, the substrate of HDAC5, at theMaf promoter
(Fig. 6H). Finally, we tested whether Nrg1 signaling regu-
lates HDAC5 phosphorylation. In serum-starved S16
cells, Nrg1 stimulation induced phosphorylation and nu-
clear exclusion of HDAC5 (Fig. 6G). These results indicate
that CaM kinase downstream from Nrg1 phosphorylates
HDAC5 and thus derepress Maf expression in Schwann
cell lines.
To confirm these findings in vivo, we first analyzed sci-
atic nerve tissues of developingmice to assessCaMkinase
activity. Antibodies that robustly recognize phosphorylat-
ed (activated) CaMKIV, the target of CaM-KK, in tissue
samples are available and were used for this analysis.
The total amount of CaMKIV protein decreased during de-
velopment, while the level of phosphorylated CaMKIV
gradually increased. Thus, the overall activity of CaMKIV
(phosphorylated CaMKIV normalized by total CaMKIV)
increased during development (Supplemental Fig. S6G).
Analysis of sciatic nerve tissues of ΔErbB2 mice revealed
decreased CaMKIV and HDAC5 phosphorylation (Fig. 6I).
Thus, Nrg1/ErbB signaling phosphorylates CaMKIV and
HDAC5 in Schwann cells during myelination. We next
verified Nrg1/ErbB-dependent HDAC5 recruitment and
histone H3 acetylation at the Maf promoter in sciatic
nerve tissue. ChIP-qPCR demonstrated that HDAC5
binding was increased, whereas histone H3 acetylation
was decreased in sciatic nerves of ΔErbB2 mice (Fig. 6J,
K). Thus, the mechanism identified in Schwann cell lines
is also important in vivo.
Maf stability is regulated by Nrg1/MAPK
We also investigated the second mechanism by which
Nrg1 controls Maf; namely, Nrg1-dependent post-tran-
scriptional regulation. In RT4 cells, inhibition of ErbB2
decreased the amount of transfected Flag-Maf protein
but not Flag-tdTomato (Fig. 7A). Reduction ofMaf protein
levels was reversed by the proteasome inhibitor MG132
but not by a lysosomal protease inhibitor (Fig. 7B). In con-
cordance with this, ubiquitination of Maf was increased
by ErbB2 inhibition, indicating that ErbB2 regulates Maf
stability through the ubiquitination–proteasome pathway
(Fig. 7C).
In myeloma cells, Maf stability is regulated by GSK3
phosphorylation, which triggers ubiquitination and deg-
radation (Herath et al. 2014). Since AKT antagonizes
GSK3 (Cross et al. 1995), we first tested whether the
Nrg1–AKT–GSK3 axis stabilizes Maf. Constructs encod-
ing Maf wild type and Maf4SA, a mutant in which all
four Ser/Thr residues phosphorylated by GSK3 are substi-
tuted with alanine, were transfected into RT4 cells, and




Figure 7. Maf stability is regulated by
Nrg1/MAPK. (A) ErbB2 inhibition destabi-
lizes Maf protein. RT4 cells transfected
with expression constructs encoding Flag-
Maf or Flag-tdTomatowere incubated over-
night with ErbB2 inhibitor. (B) Maf is de-
graded through a proteasome-dependent
pathway upon ErbB2 inhibition. RT4 cells
treated with ErbB2 inhibitor were incubat-
ed with MG132 (proteasome inhibitor)
or chloroquine (lysosomal inhibitor) for
4 h. (C ) ErbB2 inhibition induces Maf ubiq-
uitination, as assessed by an ubiquitination
assay using RT4 cells transfected with ex-
pression constructs encoding HA-tagged
ubiquitin and Flag-tagged Maf, as indicat-
ed. (D) GSK3 target sites are required for
Maf destabilization by ErbB2 inhibition.
RT4 cells were transfected with Maf
cDNA (wild type or 4SA mutant) and incu-
bated with ErbB2 inhibitor. (E,F ) ErbB2 in-
hibition destabilizes Maf in a GSK3-
independentmanner. RT4 cells transfected
with Maf cDNA were incubated with
ErbB2 inhibitor alone or together with the
GSK3 inhibitor CHIR99021 (E) or SB-
216763 (F ). (G) MAPK pathway inhibition
destabilizes Maf protein. RT4 cells trans-
fected withMaf cDNAwere incubated with the indicated inhibitors. (H) Acute inhibition of MAPK destabilizesMaf in vivo. P8 neonates
were intraperitoneally injected with vehicle or trametinib. Sciatic nerve tissue was isolated 4 h after injection and analyzed by Western
blotting. (I ) Quantification of H. The error bar indicates SEM. Unpaired two-tailed Student’s t-test with 95% confidence interval was
performed. (∗∗∗) P < 0.001. (S.E.) Short exposure; (L.E.) long exposure.
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type Maf, but not the Maf4SA mutant, was efficiently de-
stabilized by ErbB2 inhibition (Fig. 7D). As anticipated,
two independent GSK3 inhibitors (CHIR99021 and
SB-2167639) markedly increased the basal level of trans-
fected Maf protein, but, unexpectedly, Maf was still effi-
ciently destabilized by ErbB2 inhibition (Fig. 7E,F). To
analyze this further, we used additional inhibitors and ob-
served that U0126, a MAPK inhibitor that does not inhib-
it AKT, destabilized Maf to a level comparable with the
one observed after ErbB2 inhibition (Fig. 7G). Nrg1 treat-
ment markedly stabilized transfected Flag-Maf protein in
S16 and primary Schwann cells (Supplemental Fig. S7A),
and theMAPK inhibitor abrogated the effect (Supplemen-
tal Fig. S7B).
Next, we acutely inhibited MAPK to verify the effect of
the inhibition in vivo. For this purpose, we switched to
trametinib, a newly developed potent inhibitor of the
MAPK pathway. Four hours after intraperitoneal injection
of trametinib into P8 neonates, ERK phosphorylation was
abolished. Importantly, this short-term treatment low-
ered the levels of Maf protein (Fig. 7H,I). Notably, the
phospho-Erk levels in individual vehicle-treated mice
were somewhat variable, which largely correlated with
Maf levels. Although Maf protein was considerably re-
duced, due to the short duration of the drug treatment,
steady-state levels of cholesterol biosynthesis genes
were unchanged (data not shown). Taken together, our re-
sults show that the MAPK pathway downstream from
Nrg1 signaling stabilizes Maf in vitro and in vivo.
Discussion
Coordination of the myelination program by Nrg1
signaling
Schwann cells have a particularly high demand for choles-
terol during myelination and have to coordinate myelin
and cholesterol production. Here, we identify Maf as a
new gene required for myelination.Maf is specifically in-
duced inmyelinating Schwann cells, and its loss results in
hypomyelination. ΔMaf mice also display other features
typical of myelination deficits, such as a decreased axon
conduction velocity and the presence of tomaculae.
ΔMaf nerves exhibit a major down-regulation of genes in-
volved in cholesterol synthesis. Cholesterol biosynthesis
is a rate-limiting step in myelination, and we propose
that the reduction in cholesterol biosynthesis is an impor-
tant consequence of Maf ablation in Schwann cells.
SREBP1/2, themaster transcriptional regulators of choles-
terol synthesis enzymes, were unaffected. Instead, Maf
bound to the enhancers of genes encoding cholesterol
synthesis enzymes, suggesting that Maf directly partici-
pates in their regulation. Moreover, we found that Maf is
a downstream target of the Nrg1/ErbB pathway. The
CAMK and MAPK pathways are important for the Nrg1-
dependent transcriptional and post-transcriptional
control of Maf, respectively. Collectively, our results
delineate a novel cascade regulating cholesterol synthesis
inmyelinating Schwann cells that spans from an extracel-
lular signal to chromatin (summarized in Fig. 8).
Maf regulates myelination by controlling transcription
of cholesterol biosynthesis genes
We demonstrate here that Maf regulates Schwann cell de-
velopment by regulating cholesterol biosynthesis.Maf ab-
lation severely reduced the expression of genes encoding
rate-limiting enzymes in cholesterol synthesis, such as
Hmgcr and Fdft1. Down-regulation of the key enzymes
and cholesterol was apparent during the early stages of
myelination, indicating that this reflects a primary conse-
quence of the Maf mutation. Many other aspects of the
Schwann cell-specific differentiation program were un-
changed by the mutation, such as expression of myelin
genes or transcription factors controlling myelin genes,
AKT or MAPK signaling, and overall protein synthesis.
The phenotype of Maf mutant mice is milder than the
one observed when the de novo cholesterol biosynthesis
program is completely eliminated (e.g., SCAP mutants),
reflecting differences in the severity of the transcriptional
effects on cholesterol synthesis genes.
An important question for future investigation iswheth-
er and howMaf cooperates with other transcriptional reg-
ulators duringmyelination. For example, it is possible that
Maf cooperateswith SREBP1/2 at the chromatin, since the
effect of Maf overexpression on cholesterol biosynthesis
genes becamemore pronounced when cells were depleted
of cholesterol, a condition that increases SREBP1/2 activ-
ity. Key Schwann cell transcription factors such as Egr2
candirectly participate in the activation of cholesterol bio-
synthesis genes (Leblanc et al. 2005). We therefore com-
pared Maf-binding sites and published ChIP-seq (ChIP
combined with high-throughput sequencing) data for
Sox10 and Egr2 in cholesterol synthesis genes of sciatic
Figure 8. Orchestration of cholesterol biosynthesis by Nrg1/
Maf. Nrg1 signaling increases cholesterol synthesis in myelinat-
ing Schwann cells through a Maf-mediated mechanism that de-
pends on a combinatorial effect of the Ca2+ and MAPK
pathways. See the Discussion for further details.
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nerve tissues (Srinivasan et al. 2012; Lopez-Anido et al.
2015) and observed that the distinct genes were bound by
various combinations of Maf, Sox10, and Egr2 (Supple-
mental Table S1). It is thus possible that Maf cooperates
with Sox10, Egr2, and SREBP1/2 to regulate cholesterol
biosynthesis.
Maf expression is modulated by Nrg1 in myelinating
Schwann cells
Weprovide evidence thatCaMkinase activity derepresses
Maf and that this derepression occurs in a Nrg1/CaM ki-
nase-dependent manner. Nrg1/CaM kinase antagonizes
the action of HDAC5 by phosphorylation, which seques-
ters HDAC5 in the cytoplasm. Accordingly, acetylated
H3 levels at the Maf promoter were reduced after
HDAC5 was silenced in cultured cells, and this was also
observed after ErbB2 ablation in nerve tissue. It should
be noted thatMaf is not expressed during early Schwann
cell development but is robustly induced during myelina-
tion (Fig. 1B). By comparison, the effect of Nrg1–ErbB2/3
signaling on Maf mRNA is weaker (50%–60% both in
vivo and in culture). Thus, an Nrg1/ErbB-independent
transcriptional control ofMaf is executed when myelina-
tion commences, possibly by well-characterized tran-
scription factors that control entry into myelination,
such as Egr2, Oct-6, or Brn2. Indeed, previous ChIP-seq re-
sults show that Sox10 and Egr2 bind to theMaf promoter
(Supplemental Table S1). A similar mechanism—the
combined action of lineage-specific transcription factors
and derepression of chromatin through signaling mole-
cules—is used during muscle differentiation (McKinsey
et al. 2000) and thusmight represent a common regulatory
mechanism in development.
Control of Maf stability by the MAPK pathway
Our results suggest the existence of a novelMAPK-depen-
dent pathway that stabilizesMaf. EvenwhenMaf was sta-
bilized throughGSK3 inhibition, ErbB2 signals are needed
to fully stabilize theMaf protein.We introduced reversion
mutations into Maf4SA, which restore individual Ser/Thr
residues targeted by GSK3. This showed that Maf4SA and
all four reversion mutants were no longer destabilized
by ErbB2 inhibition (Supplemental Fig. S7C). Thus,
Nrg1–MAPK and GSK cooperate to fully stabilize Maf.
Notably, we did not notice differences in the mobility of
Maf protein in ΔErbB2 nerves or cells treated with
MAPK/ErbB2 inhibitor, indicating that the Nrg1–MAPK
pathway does not activate a Maf phosphatase. The stabili-
zation of Maf protein by Nrg1–MAPK signaling is very
acute, which excludes transcriptional mechanisms.
Thus, a plausible mechanism is that MAPK activity acts
downstream from Maf phosphorylation; for instance, by
inhibiting an E3 ubiquitin ligase or activating a deubiqui-
tinase. The MAPK pathway is known to stimulate myeli-
nation by affecting transcription and boosting protein
synthesis (Grossmann et al. 2009; Newbern et al. 2011;
Sheean et al. 2014). Here we show that MAPK activity




All experiments were conducted according to regulations estab-
lished by the Max Delbrück Centre for Molecular Medicine and
the Landesamt für Gesundheit und Soziales. The Mafflox,
MafLacZ, ErbB2flox, Egr2-Cre, and Dhh-Cre lines have been de-
scribed previously (Garratt et al. 2000; Voiculescu et al. 2000; Jae-
gle et al. 2003; Wende et al. 2012). P14 Wistar rat neonates were
used for the Maf ChIP experiments.
Cell lines, constructs, transfection, and retrovirus generation
S16 and RT4-D6P2T were purchased from American Type Cul-
ture Collection (ATCC) and were maintained according to the
guidelines provided by ATCC. 293T cells were a kind gift from
Dr. Claus Scheidereit (Max Delbrück Centre for Molecular Med-
icine, Germany) and were maintained in high-glucose DMEM
(Gibco) containing 10% fetal bovine serum and penicillin/strep-
tomycin. Methods for isolating and culturing primary Schwann
cells have been described (Sheean et al. 2014). The list of chemi-
cals used in this study is in the Supplemental Materials.
MouseMaf cDNAwas cloned into the pcDNA3.1 plasmid con-
taining a Flag tag. Expression constructs encoding Myc-tagged
Maf (wild type and 4SA mutants) were a kind gift from Dr. Celio
Pouponnot and Dr. Laure Lecoin (both at Curie Institute, France).
The plasmid encoding HA-Ub was a kind gift from Dr. Claus
Scheidereit. Flag-tagged HDAC4SA and HDAC5SA expression
constructs were purchased from Addgene.
Fugene HD (Promega, E2311) and Lipofectamine RNAiMAX
(Thermo Fisher, 13778075) were used for DNA and siRNA
transfections experiments, respectively, according to the manu-
facturer’s guidelines. siRNAs were synthesized from Eurofins
(Luxemburg) with a dTdT overhang at the 3′ ends. The targeting
sequences of the siRNAs used in this study are listed in Supple-
mental Table S3.
For retrovirus generation, 293T cells were transfected with a
1:1 ratio of retrovirus construct and a helper virus vector
(pCLEGO). The media were changed 1 d after transfection, and
retroviruses were collected for 2 d. Supernatants were cleared
by centrifuging at 3000 rpm for 20 min. Polybrene (Millipore,
TR-1003-G) was added at 5 µg/mL concentration, and target cells
were infected for 1 d. On the following day, cells were selected
with 2–3 µg/µL puromycin (Sigma-Aldrich, P8833). For infecting
primary Schwann cells, viruses were collected in Schwann cell
culture medium, and the supernatants were further concentrated
using Retro-X concentrator (Clontech, 631455).
Myelin thickness and intermodal distance measurements
Electron microscopy was performed as described (Topilko et al.
1994). The circumference of individual myelinated fibers and
their axons was then measured from electron microscopy photo-
graphs. Internodal distancewas determined using single teased fi-
bers from osmicated sciatic nerves. Internodal distance and fiber
diameter were measured from bright-field microscopy images.
The average relationship between the axon diameter and the
thickness of the fiber was determined for both control and
ΔMafmice from the myelin thickness measurements. This rela-
tionship between fiber diameter and axon diameter was then
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used to calculate the axon diameter of the teased fibers. The inter-
modal distance was then plotted against the axon diameter.
Immunohistochemistry
Sciatic nerves were freshly isolated and submerged in Zambonis
fixative for 10 min at room temperature. Nerves were washed
in PBS and then either directly teased on slides or incubated in
20% sucrose overnight. Cryoprotected sciatic nerves were then
embedded in OCT and frozen on dry ice/ethanol. Twelve-micro-
meter frozen sections were prepared, dried, and stored at −80°C.
Immunohistochemistry was then performed as described previ-
ously (Wende et al. 2012). The list of the primary antibodies
used is in Supplemental Table S2. Secondary antibodies were ob-
tained from Dianova. Fluorescence was visualized by laser-scan-
ning microscopy (Carl-Zeiss, LSM 700) using Zen 2009 software.
Microarray hybridization and data analysis
Total RNAwas isolated from P8 sciatic nerves using Trizol (Invi-
trogen) and RNeasy (Qiagen). Sciatic nerves of five mice of each
genotype (ΔErbB2 and littermate controls and ΔMaf and litter-
mate controls) were processed and hybridized to Affymetrix
Mouse Genechip 1.0 ST arrays as specified by the manufacturer.
Microarray data were analyzed using the Partek Genomics suite.
The microarray data were normalized using RMA (robust multi-
array average). Batch effects between ErbB2 andMaf sampleswere
removed using the control samples of each genotype. Differential
expression was analyzed using a parametric analysis of variance
(ANOVA) with Benjamini Hochberg false discovery rate (FDR)
(https://www.jstor.org/stable/2346101). Post-hoc comparisons
were done using the LSD (least significant difference) test.
For clustering, differentially expressed genes with an FDR <
0.01 were considered (1092 genes). K-means clustering was then
performed on normalized average expression values of each geno-
type (mean of 0 and standard deviation of 1). The data were
grouped into six clusters based on Davies-Bouldin scores. The
clusters were then hand-sorted. Heat maps were generated using
R and the pheatmap package. GO analysis of the genes within the
clusters was performed using DAVID (Huang da et al. 2009).
Electrophysiology
The conduction velocities of single nerve fibers within the
saphenous nerveweremeasured using an ex vivo skin nerve prep-
aration (Milenkovic et al. 2008). We made recordings from func-
tionally isolated single units in teased fibers of the saphenous
nerve that respond to mechanosensitive stimuli of the skin. For
each single unit, a metal electrode was placed in the receptive
field to electrically evoke spikes recorded in the teased filament
between 20 and 40 mm distant from the stimulation site. The
conduction velocity of individual fibers in meters per second
was then calculated by dividing the conduction distance in milli-
meters by the electrical latency in milliseconds. In each ex vivo
preparation, the conduction velocities of both fast- and slower-
conducting axons were measured in a randomized fashion, blind
to the animal’s genotype.
GC-MS
Nerve material was homogenized in extraction buffer (50 mg of
nerve material per 1 mL of extraction buffer [5:2:1 v:v:v]:
LC-MS-grade methanol, chloroform ReagentPlus 99.8% [Sigma-
Aldrich], LC-MS-grade water); 2 mg/mL cinnamic acid (Sigma-
Aldrich) was added as an internal standard. For phase separation,
an additional four parts of water was added and shaken at
750 rpm for 60 min at 4°C followed by centrifugation at 5000g
for 10min to separate the polar (top), lipid (bottom), and interface
(tissue debris) layers. Lipid phases were dried under vacuum for
12 h and processed and analyzed using GC-MS.Metabolite analy-
ses were performed by a Pegasus III mass spectrometer (LECO)
equipped with an Agilent 6890N gas chromatograph and a VF-
5ms column with 30-m length and 250-µm inner diameter (Agi-
lent). Samples were prepared as described in Kempa et al. (2009),
and 1 µL of sample was injected into a baffled liner (Gerstel)
with a 1:5 split ratio under a helium flow of 1.2 mL/min. The
oven was heated from 70°C to 350°C, with 5°C/min to 120°C
and 7°C/min to 350°C, followed by a 2-min hold time. Scan rates
of 20 Hz and mass ranges of 70–600 Da were used. The GC-MS
chromatograms were initially processed with the ChromaTOF
software (LECO). An in-house database was used to identify sub-
stances in chromatograms achieved from the lipid phase with re-
spect to the spectrum similarity and retention index. Data
matrices for relative quantification were extracted from the
mass spectra using MetMax software (Kempa et al. 2009).
In vivo SILAC chase experiment for protein translation ratemeasurement
In vivo labeling and subsequent mass spectrometry analysis were
performed as described previously (Sheean et al. 2014). For data
analysis, nonnormalized SILAC ratios from proteins with two or
more SILAC counts were used. Labeling efficacy was the same
in both samples and therefore not corrected for. Differences in
overall nerve protein content was accounted for by performing
spike-in experiments. Additionally, we normalized the SILAC
ratios to neuron-derived proteins (Nefl, Tubb3, Nefh, and
Nefm). Finally, GO annotation was added to each protein, and
contaminating blood-derived proteins were excluded. Proteins
were subgrouped based on eitherGOterms ormanual annotation.
Western blotting, ChIP, RT-qPCR, and ubiquitination assay
Western blotting, ChIP, RT-qPCR, and ubiquitination assay were
performed following standard protocols. For further details, see
the Supplemental Material.
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